Literature DB >> 16568156

A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey.

K C Maki1, Michael H Davidson, Mary R Dicklin.   

Abstract

BACKGROUND: The United States' National Cholesterol Education Program (NCEP) Adult Treatment Panel III and the Canadian Working Group on Hypercholesterolemia and Other Dyslipidemias (CWG) have each issued guidelines for the treatment of dyslipidemia.
OBJECTIVE: The present analysis compared the percentage of patients reaching target lipid levels according to NCEP and CWG guidelines among participants of the NCEP Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II, a survey performed in the United States.
METHODS: American physicians who were high prescribers of lipid-modifying medications (n=376) each enrolled 10 to 20 consecutive patients from February to September 2003. Medical information, laboratory measurements and treatment plans associated with a single office visit were entered into a personal digital assistant and uploaded to a central database via the Internet.
RESULTS: Under both sets of guidelines, treatment success was strongly related to risk category (P<0.001). Treatment goal achievement in the low-risk (zero or one risk factor) and moderate-risk (two or more risk factors) categories was not substantially different between NCEP and CWG guidelines; however, in the high-risk category (coronary artery disease [CAD] and risk equivalents [RE]), CWG treatment goals were met less frequently than NCEP goals. NCEP combined low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol treatment goals were met by 39% of hypertriglyceridemic patients (27% in the CAD + CAD RE category). CWG combined low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio treatment goals were met by 38% of hypertriglyceridemic patients (19% in the CAD + CAD RE category).
CONCLUSIONS: These data indicate substantial underachievement of treatment goals by patients at high risk under both the CWG and NCEP guidelines. The lower frequency of treatment success in high-risk patients according to the CWG definition indicates that more aggressive treatment is needed to reach CWG goals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16568156      PMCID: PMC2560524          DOI: 10.1016/s0828-282x(06)70916-3

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  23 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians.

Authors:  JoAnn E Manson; Patrick J Skerrett; Philip Greenland; Theodore B VanItallie
Journal:  Arch Intern Med       Date:  2004-02-09

3.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

Authors:  Jacques Genest; Jiri Frohlich; George Fodor; Ruth McPherson
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262

4.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

5.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

Review 6.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

7.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

8.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

9.  Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001.

Authors:  Michel R Joffres; Tripthi V Kamath; G Rhys Williams; Jill Casey; Lawrence W Svenson
Journal:  Can J Cardiol       Date:  2004-06       Impact factor: 5.223

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  4 in total

Review 1.  Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2013-11       Impact factor: 3.275

2.  Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome.

Authors:  Dan-Qing Yu; Shu-Guang Lin; Ji-Yan Chen; Ling Xue; Guang Li; Hao-Jian Dong; Ying-Ling Zhou
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

Review 3.  Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies.

Authors:  S Mitchell; S Roso; M Samuel; M Pladevall-Vila
Journal:  BMC Cardiovasc Disord       Date:  2016-04-26       Impact factor: 2.298

4.  Differences in statin usage and target-goal achievement between departments at the same hospital.

Authors:  Zhong Chen; Xin Wang; Zhen Ding; Peiying Fan; Genshan Ma
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.